[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoxemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoxemia":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,51,81,104,131,164,195,214,234,260,285,305,335,364,389,418,445,465,489,514,537,564,587,611,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100627695","effects-of-oxygen-supplementation-during-the-6-minute-walk-test-in-chronic-respiratory-failure-or-exertional-hypoxemia-100627695",false,"NCT07451977","Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia","Evaluation of the Effects of the Oxygen Supplementation During 6-minute Walking Test in Patients With Chronic Respiratory Failure or Exertional Hypoxiemia","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of chronic respiratory disease admitted for pulmonary rehabilitation\n* One of the following conditions at discharge:\n* Chronic obstructive pulmonary disease with exertional hypoxemia\n* Chronic obstructive pulmonary disease with chronic respiratory failure requiring long-term oxygen therapy\n* Interstitial lung disease with chronic respiratory failure requiring long-term oxygen therapy\n* Clinically stable condition for at least one month\n* Optimized medical therapy during hospitalization\n* Ability to perform the 6-minute walk test\n* Signed informed consent\n\nExclusion Criteria:\n\n* Lung diseases other than chronic obstructive pulmonary disease or interstitial lung disease\n* Resting oxygen flow requirement greater than 4 liters per minute\n* Orthopedic, neurological, or cognitive conditions that may limit walking performance\n* Recent cardiovascular or cerebrovascular events within the previous 3 months","ALL","18 Years",{"count":20,"type":21},114,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective easiness of performance, in a cohort of subjects hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and\u002For exertional hypoxemia due to chronic obstructive pulmonary disease or interstitial lung disease.\n\nResearchers will compare the walking performance during 6-minute walk test performed with the liters of oxygen administered as prescribed at rest (for patients with chronic respiratory failure) or in room air (for patients with exertional hypoxemia only), to the performance during a 6-minute walk test performed with the double the flow rate prescribed at rest, or with 2 L\u002Fmin for patients with exertional hypoxemia only. The two tests will be performed in random order, at least 3 hours apart and no later than 24 hours apart from each other.\n\nThe main outcome will be the difference between the distance walked in the two 6-minute walk test in the two conditions. Furthermore, will be also collected and compared: the oxygen saturation and heart rate every minute, the initial and final dyspnea and fatigue, as assessed by Borg scale, and the easiness of performance through a dedicated questionnaire. The estimated sample size will be 114 patients.\n\nThis study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure.",[27,28,29,30],"Chronic Respiratory Failure","Hypoxemia","Chronic Obstructive Pulmonary Disease (COPD)","Interstitial Lung Disease",[32,33,34,35,36,37],"oxygen supplementation","6-minute walk test","chronic respiratory failure","exertional hypoxemia","pulmonary rehabilitation","exercise tolerance","RECRUITING","2026-06-19",{"date":41,"type":42},"2026-06-23","ACTUAL",{"date":44,"type":42},"2026-04-02",{"date":46,"type":21},"2028-09-30",{"name":48,"class":49},"Istituti Clinici Scientifici Maugeri SpA","OTHER",6,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100632361","titrated-ambulatory-oxygen-in-fibrotic-ild-and-copd-with-isolated-exertional-hypoxemia-100632361","NCT07512687","Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia","Impact of Ambulatory Oxygen Delivery on Real-world Activity and Quality-of-life in Patients With Interstitial Lung Disease (ILD) and Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Adults \\>= 18 years old and \\\u003C= 85 years old with fibrotic ILD or COPD able to provide informed consent\n* Fibrotic ILD includes idiopathic pulmonary fibrosis, sarcoidosis, or other ILD with fibrotic changes on lung imaging (reticulations, honeycombing, traction bronchiectasis)\n* COPD participants will have fixed airway obstruction on spirometry less than 70%-predicted as per Global Initiative for Obstructive Lung Disease (GOLD) diagnostic criteria\n* Participants will self-report as being ambulatory outside of home without use of assistance device such as a cane or walker\n* Stable lung disease on stable medical therapy for preceding 3 months\n* Isolated exertional hypoxemia (SpO2 less than 89% for \\>=10 seconds) on a 6MWT conducted while breathing room air\n* Able to maintain SpO2 \\>=89% for the full duration of a 6MWT while using the the POC and portable oxygen D-tank at POC setting of no higher than 6 and D-tank flow rate no higher than 6 liters per minute\n\nExclusion Criteria:\n\n* People \\\u003C18 years old or \\>85 years old\n* Participants with mixed ILD and COPD diagnoses\n* Resting hypoxemia less than 89% while breathing room air\n* Emergency room visit or hospital admission in 3 months prior to recruitment\n* Change in medical therapy in 3 months prior to recruitment\n* Need for ambulatory assistive device such as cane or walker\n* Pregnant\n* Currently smoking or residing with a current smoker\n* Currently engaged in a pulmonary rehabilitation program\n* Participants without a smartphone compatible with the Oxiwear app (necessary to collect Oxiwear oxygen saturation data) or those with a compatible smartphone but without home wifi or cellular service plan allowing for Oxiwear data uploading","85 Years",{"count":60,"type":21},24,[24],"Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung disease which often affect how well oxygen can get from the lungs into the blood. Low blood oxygen levels often leads to shortness of breath which can affect patients' activity levels and quality-of-life. Many people with fibrotic ILD and COPD only have low oxygen levels when they are walking or exercising. Oxygen that is only used for walking or exercise is called ambulatory oxygen therapy (AOT). Laboratory studies suggest that AOT improves shortness of breath and exercise ability. However, real-world studies of AOT have not shown similar results. AOT can be given to patients through different types of equipment, most commonly oxygen tanks or portable oxygen concentrators (POCs). While previous studies have suggested that AOT does not significantly improve patients' breathing or activity in the real-world, these studies most often gave all participants the same amount of oxygen with the same device. However, patients with ILD and COPD often have very different oxygen needs during exercise, and POCs and oxygen tanks are very different in how oxygen is administered.\n\nThis trial will test the feasibility of a study to determine whether real-world activity, symptoms, and quality-of-life are different with the use of different oxygen equipment when oxygen therapy has been adjusted to meet each participants' oxygen needs. A total of 24 participants (12 with fibrotic ILD and 12 with COPD) who only have low oxygen levels with activity will be randomly assigned to 2-week periods using either no oxygen therapy or oxygen delivered by oxygen tanks or POC. This trial will provide preliminary data to support a larger clinical trial to further test how different AOT equipment titrated to meet individual patients' needs may affect real-world outcomes in people with ILD and COPD.",[30,64,28],"Chronic Obstructive Pulmonary Disease",[66,67,68,69,70],"Ambulatory Oxygen Therapy","Portable Oxygen Concentrator","Exertional Hypoxemia","6-Minute Walk Test","Real-World Activity","2026-06-08",{"date":73,"type":42},"2026-06-11",{"date":75,"type":21},"2026-07",{"date":77,"type":21},"2027-10",{"name":79,"class":49},"State University of New York at Buffalo",1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100637228","hfnc-versus-microstream-advance-nasal-cannula-for-oxygenation-during-ercp-100637228","NCT07611903","HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP","Inclusion Criteria:\n\n* Patients aged 18 to 84 years\n* ASA physical status I-III\n* Patients scheduled to undergo ERCP\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Recent history of upper respiratory tract infection\n* History of lung cancer\n* Chronic obstructive pulmonary disease\n* Asthma\n* Body mass index greater than 35 kg\u002Fm²\n* Refusal to participate in the study","84 Years",{"count":89,"type":21},74,[24],"Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal oxygen delivery and oral oxygen insufflation.\n\nThis prospective randomized study aims to compare the effectiveness of HFNC and Microstream Advance nasal cannula in maintaining oxygenation during ERCP procedures. Patients undergoing ERCP will be randomized into two groups receiving either HFNC or Microstream Advance nasal cannula oxygen support during sedation.\n\nThe primary outcomes are the incidence of desaturation and oxygen reserve index (ORi) measurements during the procedure. Secondary outcomes include time to achieve target ORi levels, respiratory complications, and procedure-related adverse events.",[93,28],"Endoscopic Retrograde Cholangiopancreatography","NOT_YET_RECRUITING","2026-05-28",{"date":97,"type":42},"2026-06-01",{"date":99,"type":21},"2026-06-29",{"date":101,"type":21},"2026-12-30",{"name":103,"class":49},"Kocaeli University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100639566","multifunctional-oropharyngeal-airway-and-hypoxemia-in-sedated-gi-endoscopy-a-multicenter-rct-100639566","NCT07623863","Multifunctional Oropharyngeal Airway and Hypoxemia in Sedated GI Endoscopy: A Multicenter RCT","Effect of a Novel Multifunctional Oropharyngeal Airway on Hypoxemia in Patients Undergoing Sedated Gastrointestinal Endoscopy: A Multicenter, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years;\n* BMI: 18-30 kg\u002Fm²;\n* ASA class I-II;\n* Scheduled to undergo elective sedated gastrointestinal endoscopy;\n* Willing to participate in this study and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed respiratory diseases, including asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, moderate or severe obstructive sleep apnea (OSA), pulmonary embolism, pulmonary edema, lung cancer, or upper respiratory tract infection, etc.;\n* Coagulation disorders, tendency for oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions;\n* Severe cardiac insufficiency (≤4 MetS);\n* Severe renal insufficiency (acute kidney injury \\[AKI\\] or chronic kidney disease \\[CKD\\] stage 4 or higher);\n* Severe hepatic insufficiency (Child-Pugh class C or worse);\n* Planned therapeutic endoscopy (e.g., polypectomy, endoscopic mucosal resection \\[EMR\\], or other therapeutic procedures);\n* Pregnancy or breastfeeding;\n* Allergy to the study drugs;\n* Emergency surgery;\n* Daily alcohol intake ≥60 grams;\n* History of psychiatric disorders: e.g., depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease;\n* Myasthenia gravis;\n* Participation in other related clinical trials within the past 3 months;\n* Refusal to participate.",true,"80 Years",{"count":114,"type":21},1518,[24],"This multicenter, prospective, randomized controlled trial aims to evaluate whether a novel multifunctional oropharyngeal airway (MOPA) reduces the incidence of hypoxemia in 1,518 adult patients (ASA I-II, aged 18-80 years) undergoing elective sedated gastrointestinal endoscopy. Patients are randomized 1:1 to receive either the MOPA (which integrates oxygen delivery, PETCO₂ monitoring, and airway support) or conventional nasal cannula with standard mouthpiece. The primary endpoint is the incidence of hypoxemia (75% ≤ SpO₂ \\\u003C 90% for \\\u003C60 seconds) during the procedure. Secondary outcomes include severe hypoxemia, hypercapnia, PETCO₂ monitoring success, airway interventions, adverse events, and satisfaction scores. The study is conducted across 29 centers in China, with centralized randomization via an EDC system, blinded outcome assessment, and statistical analysis using a two-sided alpha of 0.05 (power 90%). Results are expected to provide high-level evidence for optimizing airway management during sedated endoscopy.",[28,118],"Airway Management",[120,121,122,123],"Novel multifunctional oropharyngeal airway","Capnography \u002F PETCO₂ monitoring","Airway management","Randomized controlled trial",{"date":125,"type":42},"2026-06-03",{"date":97,"type":21},{"date":128,"type":21},"2028-06-01",{"name":130,"class":49},"Qianfoshan Hospital",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":148,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":80},"100640072","optimal-peep-for-postoperative-oxygenation-and-lung-aeration-ultrasvent-2-100640072","NCT07613177","Optimal PEEP for Postoperative Oxygenation and Lung Aeration (ULTRASVENT-2)","Effect of Positive End-Expiratory Pressure (PEEP) Level on Postoperative Oxygenation and Lung Aeration Assessed by Lung Ultrasound Monitoring: A Multicenter Randomized Controlled Trial (ULTRASVENT-2)","ULTRASVENT-2","Inclusion Criteria:\n\n* Age greater than or equal to 18 years.\n* Planned elective non-cardiac and non-thoracic surgical intervention requiring general anesthesia with mechanical ventilation.\n* Airway protection utilizing an endotracheal tube.\n* Assignment to one of the four specific surgical strata: non-abdominal, major open abdominal, major laparoscopic abdominal, or low-trauma laparoscopic surgery.\n* Baseline lung ultrasound showing no pathological findings, corresponding to a total preoperative LUS score of 0.\n* Technical feasibility of performing a postoperative lung ultrasound within the first 2 hours after the completion of surgery.\n* Signed written informed consent to participate in the clinical trial.\n\nExclusion Criteria:\n\n* Planned cardiac or thoracic surgery (e.g., coronary artery bypass grafting, valve replacement, heart transplantation, lung resection, esophageal surgery).\n* Pneumothorax diagnosed before or during the surgical procedure.\n* Inability to adequately visualize the target dorsal-basal lung zones by ultrasound due to physical limitations (e.g., morbid obesity, massive surgical dressings, anatomical anomalies, or dermatological lesions in the scanning area).\n* Presence of hydrothorax detected on the baseline preoperative ultrasound.\n* Confirmed perioperative aspiration of gastric contents or other foreign material.\n* Any pathological changes identified during the baseline ultrasound of the dorsal-basal lung regions (a total preoperative LUS score greater than 0).\n* Requirement for massive blood transfusion during the surgery, defined according to local institutional criteria.\n* Surgical interventions directly involving or violating the diaphragm.\n* Expected inability to conduct reliable postoperative clinical and ultrasound assessments (e.g., need for deep sedation preventing wakefulness and contact, or planned transfer to another facility).",{"count":140,"type":21},360,[24],"The purpose of this multicenter, randomized controlled trial (ULTRASVENT-2) is to evaluate the effect of different positive end-expiratory pressure (PEEP) levels on postoperative oxygenation and lung aeration in adult patients undergoing elective non-cardiac and non-thoracic surgery under general anesthesia. Moving away from traditional binary outcomes, this study utilizes a continuous functional metric, the non-invasive oxygenation index SpO2\u002FFiO2 (S\u002FF ratio), as the primary endpoint to precisely capture the degree of respiratory function preservation.\n\nPatients will be stratified into four distinct surgical cohorts based on the type and aggressiveness of the procedure: non-abdominal surgery, major open abdominal surgery, major laparoscopic abdominal surgery, and low-trauma laparoscopic surgery. This adaptive design aims to investigate how protective PEEP strategies interact with varying degrees of surgical trauma and intraoperative pneumoperitoneum, allowing the optimization of mechanical ventilation parameters for routine clinical practice.",[144,145,146,147,28],"Postoperative Complications","Respiratory Insufficiency","Pulmonary Atelectasis","Positive-End Expiratory Pressure",[149,150,151,152,153],"Lung ultrasound","S\u002FF ratio","Perioperative lung protection","Laparoscopic surgery","Open laparotomy","2026-05-23",{"date":156,"type":42},"2026-05-29",{"date":158,"type":21},"2026-07-01",{"date":160,"type":21},"2026-12-20",{"name":162,"class":163},"Moscow Multidisciplinary Clinical Center \"Kommunarka\"","OTHER_GOV",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":80},"100639926","predictors-of-clinically-relevant-hypotension-and-hypoxemia-during-propofol-based-diagnostic-gastrointestinal-endoscopy-100639926","NCT07613073","Predictors of Clinically Relevant Hypotension and Hypoxemia During Propofol-Based Diagnostic Gastrointestinal Endoscopy","Independent Predictors of Clinically Relevant Hypotension and Hypoxemia During During Propofol-Based Diagnostic Gastrointestinal Endoscopy: A Prospective Cohort Study","PRO-GI SAFE","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for diagnostic esophagogastroduodenoscopy, diagnostic colonoscopy, or combined diagnostic upper and lower gastrointestinal endoscopy\n* Planned use of propofol as the primary sedative\u002Fanesthetic agent for diagnostic gastrointestinal endoscopy\n* American Society of Anesthesiologists physical status I to III\n* Able to provide informed consent or has legally authorized representative consent according to local regulations\n\nExclusion Criteria:\n\n* Therapeutic or interventional gastrointestinal endoscopy, including ERCP, EUS-guided intervention, EMR, ESD, endoscopic hemostasis, or polypectomy\n* Planned sedation\u002Fanesthesia without propofol as the primary sedative\u002Fanesthetic agent\n* Known allergy or contraindication to propofol\n* Pregnancy or suspected pregnancy\n* Emergency condition requiring immediate advanced airway control before the procedure\n* Inability to obtain essential baseline or outcome data required for the study",{"count":173,"type":21},1000,"OBSERVATIONAL","This prospective observational cohort study will evaluate the incidence and independent predictors of clinically relevant hypotension and hypoxemia during propofol-based diagnostic gastrointestinal endoscopy in adult patients at a tertiary referral hospital in Vietnam. Participants undergoing diagnostic upper gastrointestinal endoscopy, colonoscopy, or combined diagnostic procedures with propofol administration will be followed from pre-procedure assessment through the early recovery period. The study will assess demographic, clinical, airway, procedural, and sedation-related variables associated with clinically relevant cardiopulmonary adverse events.",[177,28],"Hypotension",[179,180,181,182,183,184,185,186],"Propofol sedation","Gastrointestinal endoscopy","Colonoscopy","Upper gastrointestinal endoscopy","Oxygen desaturation","Hemodynamic instability","Prospective cohort","Procedural sedation","2026-05-21",{"date":156,"type":42},{"date":190,"type":21},"2026-05-15",{"date":192,"type":21},"2026-10-30",{"name":194,"class":49},"Bach Mai Hospital",{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":212,"locationsCount":4},"100639114","effect-of-different-bed-head-angles-on-intraoperative-hypoxemia-in-patients-undergoing-painless-gastroenteroscopy-a-prospective-randomized-controlled-study-100639114","NCT07594951","Effect of Different Bed Head Angles on Intraoperative Hypoxemia in Patients Undergoing Painless Gastroenteroscopy: A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Planned to undergo painless (sedated) gastrointestinal endoscopy\n3. Signed informed consent form\n4. American Society of Anesthesiologists (ASA) Physical Status classification I to III\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Emergency examination or inadequate bowel preparation\n3. Baseline peripheral oxygen saturation (SpO₂) \\\u003C 95%\n4. Patient or family members refuse to participate in the study",{"count":202,"type":21},400,[24],"Abstract:\n\nObjective: This study aimed to investigate the effect of different bed angles (0° vs. 15°) on the incidence of intraoperative hypoxemia in patients undergoing gastroscopy and colonoscopy. A prospective randomized controlled trial was conducted to evaluate the impact of patient positioning on respiratory safety, providing evidence for individualized anesthesia management.\n\nBackground:\n\nWith the increasing popularity of painless gastrointestinal endoscopy, hypoxemia has become a major safety concern in anesthesia management, particularly in elderly and obese patients. Studies have shown that the incidence of hypoxemia can exceed 26%, highlighting the importance of optimizing respiratory safety during anesthesia.\n\nMethods:\n\nA total of 400 patients scheduled for painless gastrointestinal endoscopy were recruited and randomly assigned to a control group (0° left lateral position) or an experimental group (15° left lateral position). Baseline data were recorded preoperatively. Intraoperative vital signs were monitored, and the occurrence of hypoxemia and other complications was documented. Data were collected and processed in a blinded manner, followed by statistical analysis using SPSS 26.0.",[28],"2026-05-18",{"date":208,"type":42},"2026-05-19",{"date":210,"type":21},"2026-05-01",{"date":158,"type":21},{"name":213,"class":49},"Xiangya Hospital of Central South University",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":231,"locationsCount":80},"100549351","investigation-of-skin-pigmentation-effect-on-performance-of-masimo-pulse-oximetry-inspire-100549351","NCT06432881","Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)","Inclusion Criteria:\n\n* Subject is 18 years of age or older.\n* Subject is receiving care in an intensive care unit.\n* Subject with an arterial catheter in place.\n* Subject is experiencing hypoxemia as defined by 1) need for supplement oxygen or 2) peripheral oxygenation ≤ 94% on room air\n\nExclusion Criteria:\n\n* Subjects in whom pulse oximetry cannot be reliably performed on both the third and fourth digit on the hand ipsilateral to the arterial line, precluding application of the sensor (e.g., amputation and deformity).\n* Subjects with a skin condition affecting the digits, where the sensor is applied, which would preclude sensor placement as standard of care (e.g., psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown, etc.).\n* Subjects with distinct geographic variances in skin pigmentation (e.g., vitiligo) on the digit where the sensor is applied, which would preclude sensor placement as standard of care.\n* Subjects with nail polish or acrylic nails on the digits where sensor needs to be applied.\n* Subjects with known allergic reactions to adhesive tapes.\n* Subjects with arterial catheter placed in a lower extremity.\n* Subjects not suitable for the investigation at the discretion of the investigator or the clinical team.","89 Years",{"count":222,"type":21},152,[24],"The objective of this study is to evaluate the performance of Masimo RD SET® SpO2 sensors in subjects with light and dark skin pigmentation in the intensive care therapeutic area.",[28],"2026-05-14",{"date":206,"type":42},{"date":229,"type":42},"2024-01-08",{"date":158,"type":21},{"name":232,"class":233},"Masimo Corporation","INDUSTRY",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":80},"100638504","the-role-of-ultrasonographic-tracheal-measurements-in-predicting-hypoxemia-during-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-100638504","NCT07587736","The Role of Ultrasonographic Tracheal Measurements in Predicting Hypoxemia During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration","The Role of Ultrasonographic Tracheal Measurements in Predicting Hypoxemia During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients scheduled for elective EBUS-TBNA\n* Patients who provide written informed consent\n* Patients with ASA physical status I-III\n* Patients aged ≥18 years\n\nExclusion Criteria:\n\n* Tracheal stenosis or significant airway obstruction\n* History of tracheostomy\n* Use of home oxygen therapy\n* Pre-procedural SpO₂ \\\u003C 90% on room air\n* History of prior thoracic surgery\n* Diagnosis of congestive heart failure\n* Presence of pleural effusion\n* FEV1 \\\u003C 40%\n* COPD patients classified as GOLD stage 3-4\n* Restrictive lung disease (FVC \\\u003C 50%)\n* Advanced pulmonary hypertension\n* History of surgery affecting neck anatomy\n* Tracheal deviation due to large thyroid or mediastinal mass\n* ASA physical status IV\n* Pregnancy\n* EBUS performed under general anesthesia (with endotracheal intubation or laryngeal mask airway)\n* Hemodynamic instability",{"count":242,"type":21},300,"Bronchoscopic procedures performed under endobronchial ultrasound (EBUS) guidance are widely used minimally invasive diagnostic methods for the evaluation of mediastinal lymph nodes. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) is an indicated procedure for the diagnosis, staging, and histopathological characterization of primary or metastatic tumors. The procedure is generally performed under moderate or deep sedation to enhance patient comfort and optimize procedural success. Deep sedation has been shown to be a safe and effective approach in terms of respiratory complications in both younger and elderly patients.\n\nHowever, hypoxemia may develop during EBUS procedures due to mechanisms such as mechanical airway obstruction, sedation-related ventilatory depression, and ventilation-perfusion mismatch. A decrease in oxygen saturation is frequently observed during bronchoscopic procedures, with reported rates of up to 94%. Studies have also reported a hypoxemia rate of approximately 25% during EBUS, even with the use of a nasopharyngeal oxygen cannula. Therefore, maintaining adequate oxygenation throughout the procedure is of critical importance. In patients receiving sedation under spontaneous respiration, oxygen support is typically provided via low-flow systems such as nasal cannulae, which can generally deliver flows of up to 15 L\u002Fmin.\n\nIt has been reported that a fiberoptic bronchoscope occupies approximately 10% of the tracheal cross-sectional area and about 15% at the level of the cricoid ring, leading to partial obstruction. EBUS endoscopes have a larger outer diameter and, in addition, may exert more pronounced negative effects on respiratory mechanics due to the balloon mechanism used. The outer diameter of EBUS bronchoscopes typically ranges between 6.2 and 6.7 mm, mechanically occupying a significant portion of the tracheal lumen. This may restrict tracheal airflow, leading to partial obstruction and consequently predisposing to hypoxemia. Therefore, identifying objective anatomical predictors that can predict the development of hypoxemia is of clinical importance. However, to the best of our knowledge, no study in the literature has statistically investigated the relationship between tracheal measurements and hypoxemia occurring during EBUS.\n\nIn this study, the investigators aim to investigate the relationship between pre-procedural tracheal diameter measured by ultrasonography (USG) and the EBUS outer diameter\u002Ftracheal diameter ratio (airway occupancy ratio) with the development of hypoxemia during the procedure in patients undergoing EBUS-TBNA. Additionally, it is aimed to determine the optimal tracheal diameter cutoff value that may predict the development of hypoxemia.\n\nStudy Design and Patient Population This study will be conducted in accordance with the Declaration of Helsinki and will be carried out at SBÜ Ankara Atatürk Sanatoryum Training and Research Hospital after obtaining approval from the institutional ethics committee. The study is planned as a prospective observational cohort study. Adult patients scheduled to undergo EBUS-TBNA will be included.\n\nThe following parameters will be recorded:\n\n* Age\n* Sex\n* Body mass index (BMI)\n* FEV1 value\n* Baseline SpO₂\n* Lowest recorded SpO₂\n* Systolic\u002Fdiastolic\u002Fmean arterial blood pressure and heart rate measured at 10-minute intervals during the procedure\n* Sedative drug doses\n* Procedure duration\n* Tracheal diameter measured by ultrasonography (USG)\n* Airway occupancy ratio (EBUS outer diameter \u002F narrowest tracheal diameter measured by USG)\n* Duration and total number of hypoxic episodes during the procedure\n* Requirement for airway interventions (jaw thrust, mask ventilation, intubation, etc.)\n* Whether nasal oxygen flow was increased in case of hypoxemia, and if so, by how many L\u002Fmin\n* Presence of cough, hiccups, secretions requiring aspiration, bronchospasm, and procedure-related bleeding\n* Whether the procedure was interrupted",[245,28,246],"ENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION","Trachea",[248,249,250,251],"ENDOBRONCHIAL ULTRASOUND","TRANSBRONCHIAL NEEDLE ASPIRATION","TRACHEAL DIAMETER","HYPOXEMİA","2026-05-11",{"date":226,"type":42},{"date":255,"type":21},"2026-05-20",{"date":257,"type":21},"2027-05-01",{"name":259,"class":163},"Ankara Ataturk Sanatorium Training and Research Hospital",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":80},"100554594","optimizing-care-in-critically-ill-at-uchealth-by-liberalizing-the-target-o2-in-mechanically-ventilated-icu-patients-100554594","NCT06501118","Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients","Inclusion Criteria:\n\n* Admission to ICU and requiring invasive mechanical ventilation\n\nExclusion Criteria:\n\n* Transferred patients from outside the UCHealth system\\*:\n* Patients with pre-existing disease that requires chronic use of positive pressure ventilation delivered through a tracheostomy\\*:\n* Pregnant women:\n* Prisoners\n* Patients receiving mechanical ventilation for less than twelve hours",{"count":267,"type":21},3600,[24],"A multimodal educational intervention to target an oxygen saturation target range (SpO2 90-96%) will reduce ventilator length of stay and reduce occult hypoxemia by increased awareness and adherence to a designated oxygen saturation target range.",[271,272,273,28,274,275],"Respiratory Failure","Acute Hypoxemic Respiratory Failure","Acute Hypoxic Respiratory Failure","Hypoxia","Hypoxic Respiratory Failure","2026-05-04",{"date":278,"type":42},"2026-05-08",{"date":280,"type":42},"2024-09-01",{"date":282,"type":21},"2026-07-31",{"name":284,"class":49},"University of Colorado, Denver",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":17,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":295,"studyType":174,"phases":4,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":301,"leadSponsor":303,"locationsCount":4},"100636686","frailty-and-intraoperative-hypoxemia-risk-in-elderly-ercp-patients-100636686","NCT07568912","Frailty and Intraoperative Hypoxemia Risk in Elderly ERCP Patients","The Predictive Value of Frailty for Intraoperative Hypoxemia in Elderly Patients Undergoing ERCP: A Two-Directional Cohort Study and Predictive Model Construction","Inclusion Criteria:\n\n1. Age 65 years or older\n2. Elective endoscopic retrograde cholangiopancreatography (ERCP) under anesthesia sedation\n3. American Society of Anesthesiologists (ASA) physical status II-IV\n4. Expected procedure duration less than 60 minutes\n5. Available and complete intraoperative pulse oximetry (SpO₂) monitoring data\n\nExclusion Criteria:\n\n1. Emergency ERCP\n2. Severe anemia (hemoglobin \\\u003C 60 g\u002FL) or conditions interfering with accurate 3. SpO₂ measurement\n\n4\\. Pre-existing severe respiratory insufficiency requiring long-term oxygen therapy 5. Unstable hemodynamics requiring continuous vasopressor infusion Impaired consciousness, delirium, or cognitive dysfunction that prevents reliable frailty assessment","65 Years",{"count":294,"type":21},701,"3 Months","Intraoperative hypoxemia is a common and serious complication during monitored anesthesia care for elective endoscopic retrograde cholangiopancreatography (ERCP), especially in older adults. Frail patients have reduced physiologic reserve and are at increased risk of life-threatening events including unplanned intubation, hemodynamic collapse, and hypoxic brain injury. However, the independent relationship between frailty and intraoperative hypoxemia during sedated ERCP remains poorly defined, and no validated risk prediction model exists for this high-risk population. This single-center, dual-cohort study will be conducted at China-Japan Friendship Hospital to evaluate whether preoperative frailty can predict intraoperative hypoxemia in patients aged 65 years and older undergoing elective ERCP. Frailty will be assessed primarily using the Frailty Index (FI), with secondary screening by the Modified Frailty Index-11 (mFI-11), Edmonton Frail Scale (EFS), Clinical Frailty Scale (CFS), FRAIL scale, and Fried phenotype. The primary outcome is intraoperative hypoxemia, defined as SpO₂ \\\u003C 90% for 5 seconds or longer. In the retrospective phase (n = 313), investigators will identify risk factors and develop a preliminary prediction model. In the prospective phase (n = 388), the model will be validated, refined, and internally tested for discrimination, calibration, and clinical utility. This study aims to establish frailty as a reliable preoperative risk marker and provide a clinically practical prediction tool to support risk stratification, personalized sedation strategies, and perioperative safety in elderly patients undergoing ERCP.",[28],{"date":299,"type":42},"2026-05-06",{"date":97,"type":21},{"date":302,"type":21},"2028-12-31",{"name":304,"class":49},"China-Japan Friendship Hospital",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":334},"100636237","effect-of-high-flow-nasal-cannula-oxygen-therapy-on-hypoxemia-in-pediatric-sedated-bronchoscopy-100636237","NCT07563075","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 1 year ≤ age ≤ 6 years,\n* Weight ≥ 10 kg,\n* Undergoing elective sedated bronchoscopy,\n* Expected procedure duration ≤ 45 minutes,\n* Written informed consent obtained from the subject's legal guardian.\n\nExclusion Criteria:\n\n* preoperative SpO₂ \\\u003C 95% on room air,\n* Already sedated and tracheally intubated,\n* Known history of pneumothorax, known congenital or acquired upper airway abnormalities (e.g., nasopharyngeal structural anomalies), or history of difficult airway,\n* Coagulation disorders or predisposition to oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions,\n* Severe cardiac insufficiency (\\\u003C 4 METs), severe renal insufficiency (requiring dialysis), diagnosed severe hepatic insufficiency, Increased intracranial pressure, or ASA classification ≥ IV,\n* Allergy to propofol or sufentanil,\n* Multiple traumatic injuries,\n* Current participation in another clinical trial,\n* Other conditions deemed unsuitable by the investigator.","1 Year","6 Years",{"count":315,"type":21},430,[24],"Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.",[28,319,320],"Pneumonia","Pulmonary Neoplasm",[322,28,323,324,325],"Bronchoscopy","Sedation","Pediatric","High-flow nasal cannula","2026-04-28",{"date":210,"type":42},{"date":329,"type":21},"2026-04-01",{"date":331,"type":21},"2027-03-31",{"name":333,"class":49},"Zhejiang University",4,{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":292,"enrollmentInfo":343,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":4},"100632539","lung-ultrasound-score-and-postoperative-pulmonary-complications-in-major-non-thoracic-surgery-100632539","NCT07515001","Lung Ultrasound Score and Postoperative Pulmonary Complications in Major Non-Thoracic Surgery","Predictive Value of Perioperative Lung Ultrasound Score for Early Postoperative Oxygen Requirement and Pulmonary Complications in Patients Undergoing Major Non-Thoracic Surgery","LUS-POSTOP","Inclusion Criteria:\n\n* Aged 18 to 65 years\n* Scheduled for elective major non-thoracic surgery\n* Undergoing surgery under general anesthesia\n* Expected surgical duration of 3 hours or longer\n* ASA physical status I-III\n* Willing to participate in the study\n* Provides written informed consent\n\nExclusion Criteria:\n\n* Patients undergoing thoracic or cardiac surgery\n* Advanced chronic lung disease (e.g., severe COPD or pulmonary fibrosis)\n* History of previous lung resection\n* Preoperative pneumonia or active pulmonary infection\n* Body mass index greater than or equal to 40 kg\u002Fm2\n* Pregnancy\n* Emergency surgery\n* Planned postoperative mechanical ventilation or intensive care unit admission\n* Refusal to participate in the study",{"count":344,"type":21},97,"This prospective observational cohort study aims to evaluate the predictive value of perioperative lung ultrasound (LUS) score in determining early postoperative oxygen requirement and pulmonary complications in patients undergoing major non-thoracic surgery. Postoperative pulmonary complications remain a significant cause of morbidity and mortality in surgical patients. Lung ultrasound is a non-invasive, bedside imaging modality that allows real-time assessment of lung aeration and pathology. This study will investigate the association between perioperative LUS score and early postoperative respiratory outcomes, including oxygen requirement and pulmonary complications.",[347,28],"Postoperative Pulmonary Complications (PPCs)",[349,350,351,144,352,353,354],"lung ultrasound","Lus Score","Perioperative Ultrasound","Oxygen Requirement","Non-Thoracic Surgery","Anesthesia","2026-03-31",{"date":357,"type":42},"2026-04-07",{"date":359,"type":21},"2026-04",{"date":361,"type":21},"2027-01",{"name":363,"class":49},"Dicle University",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":80},"100630552","real-time-end-tidal-carbon-dioxide-monitoring-for-early-warning-of-hypoxemia-in-painless-gastrointestinal-endoscopy-100630552","NCT07489157","Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy","Application of Real-Time End-Tidal Carbon Dioxide Monitoring in Painless Gastrointestinal Endoscopy","Inclusion Criteria:\n\n* patients undergoing gastroscopy and colonoscopy under intravenous anesthesia\n\nExclusion Criteria:\n\n* patients unable to wear the sampling device;\n* patients with a pulse oximetry reading (SpO2) of less than 95% when breathing ambient air\n* central nervous system abnormalities\n* patients who do not consent to participate in the study\n* poor bowel preparation.",{"count":372,"type":21},460,[24],"Using Capnography for Safer Sedation in Painless Gastrointestinal Endoscopy\n\nWhy is this study important? For procedures like painless gastroscopy and colonoscopy, patients receive sedation to ensure comfort. However, traditional monitoring (like checking heart rate and blood oxygen levels) can only detect breathing problems after they have already caused a drop in oxygen. This delay can be risky, especially for elderly patients whose breathing function is naturally weaker. This study looks at a better way to monitor patients.\n\nWhat is the new method? This study focuses on a technology called real-time end-tidal carbon dioxide (ETCO₂) monitoring, also known as capnography. It is a simple, non-invasive device that continuously measures the carbon dioxide a patient breathes out. This provides an early warning system for doctors, alerting them to breathing issues (like a pause in breathing or an airway blockage) much sooner than traditional monitors can.\n\nWhat did the study find?\n\nBased on extensive research and clinical experience both in China and internationally (including the US and Europe), integrating ETCO₂ monitoring into painless digestive endoscopy procedures leads to significant improvements in patient safety:\n\n* Reduces Risks: It can decrease the occurrence of hypoxemia (dangerously low oxygen levels) by up to 31%.\n* Early Detection: It detects breathing problems 17.6 times more often than relying on traditional observation alone, giving anesthesiologists crucial extra time (often seconds) to intervene before a patient's oxygen drops.\n* Safer for Everyone: It is particularly effective in protecting high-risk groups, such as elderly patients and those with mild obesity.\n* Better Outcomes: It helps reduce postoperative complications like nausea and vomiting, and can lead to faster recovery from anesthesia.\n\nValue for Patients, Families, and Providers:\n\n* For Patients \\& Families: This technology means a safer, more comfortable procedure with a lower risk of breathing complications. It provides peace of mind knowing your breathing is being watched continuously and carefully.\n* For Healthcare Providers: It offers a clear, real-time picture of a patient's breathing status. This supports quicker, more confident clinical decisions, reduces workload, and helps establish a standardized, quantifiable safety protocol for non-operating room anesthesia, aligning with the World Health Organization's goals for safer surgery.",[28],[377,378,379,380],"hypoxemia","End-Tidal Carbon Dioxide Monitoring","Gastrointestinal Endoscopy","Painless","2026-03-23",{"date":383,"type":42},"2026-03-27",{"date":383,"type":21},{"date":386,"type":21},"2027-01-31",{"name":388,"class":49},"Chinese PLA General Hospital",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":405,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":417},"100597252","prevention-of-desaturations-using-positive-airway-pressure-or-capnometry-during-ercp-100597252","NCT07056075","Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP","A Randomized, Controlled, Unblinded Trial Evaluating the Impact of Positive Airway Pressure and Capnometry Compared to Standard Management on the Rate of Desaturations During Nurse-administered Sedation ERCP","PrePAP-ERCP","Inclusion Criteria:\n\n* undergoing an interventional (intent) ERCP procedure\n* 18-99 years\n* Male or female\n* Nurse-administered sedation\n\nExclusion Criteria:\n\n* History of allergic reaction to Propofol\n* Tracheostomy\n* Procedure requiring intubation, general anesthesia, or anesthesiologist backup (acute exacerbation of obstructive lung disease, acute congestive heart failure, supra-glottic or sub-glottic tumor, septic shock, e.g.) according to the endoscopist in charge\n* Pregnant patients","99 Years",{"count":399,"type":21},288,[24],"Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory\u002Fairway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and\u002For monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.\n\nFor this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring\u002Ftreatment (i.e., 2 L O2\u002Fmin via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \\\u003C85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.",[403,28,404],"Desaturation","ERCP",[404,406,407,408],"Sedation-related adverse events","desaturation","trial","2026-03-21",{"date":411,"type":42},"2026-03-24",{"date":413,"type":42},"2025-07-07",{"date":101,"type":21},{"name":416,"class":49},"Karl Landsteiner University of Health Sciences",2,{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":433,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":444},"100606407","combination-of-combo-endoscopy-oropharyngeal-airway-and-hfnc-oxygenation-in-sedated-gastrointestinal-endoscopy-for-morbidly-obese-patients-100606407","NCT07175155","Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients","Combination of COMBO Endoscopy Oropharyngeal Airway and High-flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients: a Multicenter, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* BMI ≥ 35 kg\u002Fm².\n* Patients undergoing gastroscopy or gastrointestinal endoscopy.\n* The estimated duration of the procedure does not exceed 45 minutes.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Coagulation disorders or bleeding tendency (e.g., oral\u002Fnasal bleeding risk, mucosal injury, oropharyngeal obstruction) making oropharyngeal airway placement unsafe or unfeasible.\n* Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature \\>37.5°C).\n* Chronic obstructive pulmonary disease or other acute\u002Fchronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.\n* Severe organ dysfunction, including: Cardiac insufficiency (\\\u003C4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.\n* Confirmed pregnancy or current breastfeeding.\n* Known allergy to sedatives (e.g., propofol) or medical adhesives.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator.",{"count":426,"type":21},410,[24],"Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent airway collapse. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management.The purpose of this study is to investigate whether the combination of the COMBO Endoscopy Oropharyngeal Airway and High-Flow Nasal Cannula oxygenation reduces the incidence of hypoxemia in this population.",[28,430,431,432],"Esophageal Cancer","Morbidly Obese Patients","Gastric Cancer",[434,28,323,379,435],"COMBO Endoscopy Oropharyngeal Airway","high-flow nasal cannula","2026-03-09",{"date":438,"type":42},"2026-03-11",{"date":440,"type":42},"2025-10-24",{"date":442,"type":21},"2027-08-20",{"name":333,"class":49},5,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":80},"100627178","recovery-hypoxemia-after-sedated-upper-gastrointestinal-endoscopy-100627178","NCT07445256","Recovery Hypoxemia After Sedated Upper Gastrointestinal Endoscopy","Incidence, Duration, and Clinical Impact of Recovery-Period Hypoxemia Following Sedated Upper Gastrointestinal Endoscopy: A Prospective Observational Study","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Scheduled for upper gastrointestinal endoscopy (EGD) under anesthesiologist-administered sedation\n* Able to undergo post-procedure monitoring in the recovery unit\n* Provided written informed consent for participation and data use\n\nExclusion Criteria:\n\n* Colonoscopy or combined procedures (EGD + colonoscopy)\n* Emergency procedures or procedures performed under intensive care conditions\n* Requirement for endotracheal intubation, noninvasive ventilation, or advanced airway support during the procedure\n* Known severe upper airway anatomical abnormalities, facial deformity, or tracheostomy\n* Inability or refusal to provide informed consent\n* Incomplete or unavailable recovery-period oxygen saturation monitoring data",{"count":453,"type":21},100,"Sedation during upper gastrointestinal endoscopy may lead to respiratory events not only during the procedure but also in the early recovery period. Although most hypoxemic episodes are considered transient, their frequency, duration, and clinical consequences during recovery remain insufficiently defined.\n\nThis prospective observational study aims to evaluate the incidence, duration, and clinical impact of recovery-period hypoxemia following sedated upper gastrointestinal endoscopy. Hypoxemia is defined as SpO₂ \\\u003C90% lasting ≥10 seconds. Associated respiratory events and potential risk factors will be analyzed without altering routine clinical practice.",[28],"2026-02-25",{"date":458,"type":42},"2026-03-03",{"date":460,"type":21},"2026-02-28",{"date":462,"type":21},"2026-03-20",{"name":464,"class":49},"Istinye University",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":80},"100626173","medical-device-clinical-trial-without-ce-marking-to-evidence-safety-and-performance-of-the-inbentus-versatile-ventilator-in-patients-requiring-assistedcontrolled-mechanical-ventilation-and-weaning-100626173","NCT07432191","Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted\u002FControlled Mechanical Ventilation and Weaning.","Inclusion Criteria:\n\n* Participants ≥ 18 years of age at the time of consent.\n* Participants requiring invasive mechanical ventilation for a period of ≥3 hours.\n* Participants must provide written informed consent.\n\nExclusion Criteria:\n\n1. Participants requiring anesthetic delivery systems or aerosol nebulizer systems.\n2. Participants requiring modifications to the ventilator circuit, such as those treated with nitric oxide (iNO).\n3. Any participant determined by the research team to be hemodynamically unstable, defined as:\n\n   1. MAP \\\u003C 65 mmHg despite vasoactive drugs.\n   2. Systolic Blood Pressure \\> 180 mmHg.\n   3. Diastolic Blood Pressure \\> 110 mmHg.\n   4. Severe volume loss (\\>30% of blood volume) with persistent signs of hypoperfusion.\n4. Life expectancy of less than 12 months.\n5. Pregnant women at the time of informed consent.",{"count":472,"type":21},81,[24],"Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.\n\nThe 81 aldult participants are ventilated between 3 and 48 hours with invasive mechanical ventilation (IMV) in assisted\u002Fcontrolled mode and weaning under partial pressure support or volume support, followed by monitoring period until ICU discharge, hospital discharge or 30 days.\n\nThe study design differentiates between a Validation Cohort (up to 20 participants) for device validation and a Study Cohort (up to 61 participants) for safety and performance confirmation.\n\nSerious Adverse Events related to study device and\u002For its procedure is defined as the primary safety endpoint, whereas technical failure rate is defined as the primary performance endpoint.",[476,319,477,478,479,28,480],"Acute Respiratory Distress Syndrome (ARDS)","COPD (Chronic Obstructive Pulmonary Disease)","Postoperative Respiratory Distress","Hypoventilation Syndrome","Hypercapnia","2026-02-18",{"date":456,"type":42},{"date":484,"type":42},"2025-05-29",{"date":486,"type":21},"2026-11",{"name":488,"class":233},"Iconic Solutions By Murcia SL",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":80},"100608256","phase-4-steroid-treatment-for-severe-acute-respiratory-infection-star-trial-100608256","NCT07199192","Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial","A Multicenter, Randomized, Controlled Trial to Evaluate the Effectiveness and Safety of Systemic Corticosteroid Treatment for Hospitalized Patients With Severe Acute Respiratory Infection and Hypoxemia (STRIVE 003)","STAR","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Severe acute respiratory infection (SARI), defined as a suspected infection of the respiratory tract that meets each of the following 4 criteria:\n\n  1. Onset in the last 10 days AND\n  2. Results in hospitalization AND\n  3. At least one symptom or sign of respiratory illness (defined as purulent sputum, new or worsened cough, new or worsened dyspnea, tachypnea with respiratory rate ≥22 breaths per minute, rales, or bronchial breath sounds) AND\n  4. At least one symptom or sign of acute infection (defined as a temperature ≥38°C or ≤36°C, feverishness, chills, altered mental status, a white blood cell count of \\>12,000\u002Fmm3, \\\u003C4,000\u002Fmm3, or \\>10% immature neutrophils, or imaging findings consistent with acute respiratory infection).\n* Hypoxemia, defined as meeting one or more of the following at the time of eligibility assessment:\n\n  1. An oxygen saturation \\\u003C92% in a patient who does not receive chronic supplemental oxygen OR\n  2. Receipt of ≥3 liters per minute of supplemental oxygen or a fraction of inspired oxygen of ≥0.35 in a patient who does not receive chronic supplemental oxygen OR\n  3. Receipt of a flow rate of supplemental oxygen ≥3 liters per minute greater than pre-illness baseline or a fraction of inspired oxygen ≥0.10 greater than pre-illness baseline in a patient who receives chronic supplemental oxygen.\n\nExclusion Criteria:\n\n* Hospitalized for \\>72 hours\n* Primary etiology of hypoxemia is a condition other than respiratory infection\n* Known allergy or adverse reaction to systemic corticosteroids\n* Known active infection with SARS-CoV-2, known active infection with Pneumocystis jirovecii, or another established indication for systemic corticosteroids\n* Known active disseminated or pulmonary infection with Mycobacterium tuberculosis, Aspergillus, Blastomyces, Coccidioides, Cryptococcus, Histoplasma, or Strongyloides species; active systemic infection with herpes simplex virus, varicella zoster virus, or cytomegalovirus; or another established contraindication to systemic corticosteroids\n* Prisoner\n* Treatment is prioritizing end-of-life symptom management over prolongation of life\n* Investigator determines that participation in the trial is not in the patient's best interest\n* Receipt of greater than 14 days of systemic corticosteroids at a dose equivalent to greater than 10 mg of prednisolone per day in the 30 days prior to hospital presentation (i.e., chronic corticosteroids)\n* Receipt of systemic corticosteroids at a dose equivalent to greater than 30 mg of prednisolone per day on 2 or more calendar days since hospital presentation\n* Clinicians determine that the administration of systemic corticosteroids at a dose equivalent to greater than 10 mg of prednisolone per day is required, or is likely to be required in the next 24 hours, for the optimal care of the patient (such as for acute exacerbation of chronic obstructive pulmonary disease, adrenal insufficiency, asthma, continuation of chronic corticosteroid therapy, or severe shock)\n* Clinicians determine that the administration of systemic corticosteroids is not consistent with the optimal care of the patient (such as for recent peptic ulcer disease, recent gastrointestinal bleeding, severe burns, severe delirium, severe hyperglycemia or diabetic ketoacidosis, or severe hypertension)\n* Patient (or surrogate decision-maker \u002F legally authorized representative) declines to provide informed consent to participate",{"count":498,"type":21},3000,[500],"PHASE4","Multicenter, parallel-group, randomized clinical trial comparing the administration of systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days vs no corticosteroid administration among adults hospitalized with severe acute respiratory infection and hypoxemia.",[28,503],"Severe Acute Respiratory Syndrome","2026-02-17",{"date":506,"type":42},"2026-02-19",{"date":508,"type":21},"2026-03-01",{"date":510,"type":21},"2028-12-01",{"name":512,"class":513},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":521,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":80},"100560294","skin-pigmentpulse-oximeter-in-congenital-heart-disease-chd-100560294","NCT06575270","Skin Pigment\u002FPulse Oximeter in Congenital Heart Disease (CHD)","Pulse Oximetry Accuracy and Skin Pigmentation in Congenital Heart Disease: A Prospective Observational Study","Inclusion Criteria:\n\n* Pediatric patients (age less than 18 years old) with a diagnosis of CHD (cyanotic or acyanotic) who are presenting for cardiac surgery under general anesthesia with planned arterial access.\n\nExclusion Criteria:\n\n* Age greater than 18 years old\n* Emergency surgery\n* Significant preoperative anemia (hemoglobin \\\u003C8.0 g\u002FdL)\n* Preoperative hemodynamic instability (i.e., \\>1 vasoactive infusions or mechanical circulatory support)\n* The presence of any colored nail polish on the planned site of pulse oximeter placement, planned use of any intravenous dyes intraoperatively, and patient, parent, or guardian refusal.",{"count":522,"type":21},92,"Recent retrospective studies have demonstrated differences between pulse oximeter values (SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or Hispanic. These retrospective studies have limitations because self-reported race is likely not an accurate metric for level of skin pigmentation and the retrospective nature of these studies may impact the accuracy of simultaneous measures of arterial oxygen saturation and pulse oximeter values. The few prospective studies that have evaluated this issue have utilized color-matching techniques to quantify skin pigmentation, and fewer studies have directly measured skin pigmentation in relation it to pulse oximeter accuracy. The aim of this study is to prospectively measure pulse oximeter accuracy in relation to measured levels of skin pigmentation in the congenital heart disease population.",[28,525,526],"Skin Pigment","Congenital Heart Disease",[528,525,526,28],"Pulse Oximetry","2026-02-11",{"date":531,"type":42},"2026-02-13",{"date":533,"type":42},"2024-10-29",{"date":75,"type":21},{"name":536,"class":49},"Icahn School of Medicine at Mount Sinai",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":50},"100529110","health-systems-and-policy-contexts-of-medical-oxygen-100529110","NCT06169514","Health Systems and Policy Contexts of Medical Oxygen","Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)","MOXY-HSP","Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.",{"count":80,"type":21},"This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.\n\nThe the investigators seek to:\n\n1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;\n2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;\n3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.\n\nThis study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).\n\nKey informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.",[28,548,319],"Morality",[550,551,552,553,554],"Health system","Oxygen","Oxygen systems","Oxygen access","Pulse oximetry","2026-02-04",{"date":557,"type":42},"2026-02-06",{"date":559,"type":42},"2024-07-31",{"date":561,"type":21},"2027-12",{"name":563,"class":49},"Murdoch Childrens Research Institute",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":111,"sex":17,"minAge":4,"maxAge":571,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":574,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":583,"leadSponsor":585,"locationsCount":417},"100623397","efficacy-of-pimun-by-reducing-intermittent-hypoxia-events-100623397","NCT07396103","Efficacy of PIMUN by Reducing Intermittent Hypoxia Events","Clinical Study of Intermittent Hypoxia Reduction Using PIMUN: Efficacy Proof-of-Concept","Inclusion Criteria:\n\n* Preterm infants with a gestational age at birth \\\u003C34 weeks\n* Age \\\u003C30 days at the time of enrollment\n* Documented diagnosis of apnea of prematurity (AOP)\n\nExclusion Criteria:\n\n* Currently receiving mechanical ventilation (MV)\n* Presence of major congenital malformations\n* Clinically unstable or critically ill at the time of screening\n* Active sepsis or undergoing treatment for sepsis\n* Intraventricular hemorrhage (IVH) Grade \\> II\n* Receiving sedatives or anticonvulsant medications","30 Days",{"count":573,"type":21},20,[24],"The goal of this clinical trial is to learn if the use of PIMUN(medical device) works to reduce the intermittent hypoxemia of 24-34 weeks of birth gestational age babies. . It will also learn about the safety of the use of PIMUN. The main questions it aims to answer are:\n\nDoes PIMUN lower the time of oxygen saturation under 90%? What medical problems do participants have using PIMUN? Researchers will compare the use of PIMUN during 48 hours to 48 hours of usual treatments (not using PIMUN).\n\nParticipants will:\n\nUse\u002F or not use of PIMUN for a 48 hours period- randomly assigned. Regional brain oxygenation by near infrared spectroscopy (NIRS) monitoring at the first day of each 48 hours period. 4-6 hours of polysomnography at the second day of each intervention. Plasma and urine stress oxygen metabolites at the end of each 48-hours intervention.",[577,578,28],"Preterm","Apnea of Prematurity","2026-02-03",{"date":581,"type":42},"2026-02-09",{"date":280,"type":42},{"date":584,"type":21},"2026-05-31",{"name":586,"class":49},"Pontificia Universidad Catolica de Chile",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":292,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":80},"100615490","effect-of-different-oxygen-concentrations-before-extubation-after-general-anesthesia-on-hypoxemia-after-extubation-in-post-anesthesia-care-unit-100615490","NCT07293286","Effect of Different Oxygen Concentrations Before Extubation After General Anesthesia on Hypoxemia After Extubation in Post-anesthesia Care Unit","Effect of Different Oxygen Concentrations During the Recovery Period Before Extubation After General Anesthesia on Hypoxemia After Extubation in Post-anesthesia Care Unit","Inclusion Criteria:\n\n* Patients aged 18-65 years old, scheduled for elective abdominal surgery in general anesthesia with endotracheal intubation; ASA I-III grade; cardiac function 1-2 grade; 18 kg\u002Fm2 \\\u003C BMI \\\u003C 28 kg\u002Fm2; Preoperative SpO2 ≥ 94% without oxygen supplementation at rest; pre-anesthesia assessment shows no difficult airway, no difficulty with mask ventilation, no difficulty in intubation during tracheal insertion, and no difficulty in extubation as expected.\n\nExclusion Criteria:\n\n* Respiratory infection recently, or atelectasis, inflammation, fibrosis, or pleural effusion by chest CT preoperatively.\n\nHistory thoracic surgery and fractures of the sternum or ribs, chest deformity, difficulty in raising both upper limbs, or scoliosis.\n\nHigh risk of reflux aspiration. Severe hepatic or renal dysfunction (e.g., Child-Pugh class C liver disease, or requiring dialysis).\n\nLimb movement disorders. Mask ventilation or intubation difficulty during anesthesia induction. Occurrence of severe allergy, massive bleeding, suspected pulmonary embolism, pulmonary edema, myocardial injury, or cardiopulmonary arrest during surgery.\n\nCurrently participating in other clinical studies, which may have an impact on this study.\n\nInability to cooperate well for mental disorder, or hypophrenia.",{"count":595,"type":21},590,[24],"Before extubation during the anesthesia recovery period, 100% oxygen is routinely inhaled to increase the oxygen reserves, maximizing the time window for anesthesiologists to adjust strategies when they encounter hypoxemia after extubation.\n\nHowever, even inhaling a short period of pure oxygen can cause absorptive atelectasis, and may even impair the effectiveness of intraoperative protective ventilation measures continuing to post-operative period. The purpose of this study is to determine whether 30% oxygen before extubation after abdominal surgery could reduce hypoxemia incidence after extubation during the recovery period or not, compared to 100% oxygen. 590 patients scheduled to abdominal surgeries, will be randomly assigned to receive 30% or 100% oxygen concentration from the end of surgery to extubation after general anesthesia in the post-anesthesia care unit. The incidence of hypoxemia (SpO2 \\\u003C 90%) from extubation to leaving the post-anesthesia care unit (PACU) is the primary outcome.",[28],[377,600,601],"oxygen concentration","atelectasis","2025-12-16",{"date":604,"type":42},"2025-12-19",{"date":606,"type":21},"2025-12-30",{"date":608,"type":21},"2026-06-30",{"name":610,"class":49},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":292,"enrollmentInfo":618,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":628,"locationsCount":80},"100616253","preoperative-rox-index-and-postoperative-hypoxemia-in-bariatric-surgery-100616253","NCT07303205","Preoperative ROX Index and Postoperative Hypoxemia in Bariatric Surgery","Predictive Value of the Preoperative ROX Index for Early Postoperative Hypoxemia in Bariatric Surgery Patients: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Scheduled for elective bariatric surgery (laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass)\n* Body mass index (BMI) ≥ 35 kg\u002Fm²\n* ASA physical status I-III\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Acute respiratory failure, pneumonia, or active pulmonary infection\n* Receiving oxygen therapy or respiratory support (nasal cannula, CPAP, BiPAP, or high-flow oxygen) preoperatively\n* Preoperative SpO₂ \\\u003C 88% on room air\n* Significant cardiac arrhythmia, severe heart failure (NYHA class III-IV), or hemodynamic instability\n* Pregnancy, active malignancy, or current immunosuppressive therapy\n* Inability to complete postoperative follow-up or early discharge before 12-hour assessment",{"count":619,"type":21},80,"This prospective observational study evaluates whether the preoperative ROX index can predict early postoperative hypoxemia in patients undergoing bariatric surgery. Preoperative ROX measurements, along with ARISCAT and STOP-Bang scores, will be assessed for their association with hypoxemia occurring within the first 12 postoperative hours.",[28],"2025-12-11",{"date":624,"type":42},"2025-12-24",{"date":626,"type":21},"2025-12-25",{"date":508,"type":21},{"name":464,"class":49},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":17,"minAge":636,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":639,"briefSummary":641,"conditions":642,"keywords":643,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":80},"100595852","phase-2-inhaled-treprostinil-tyvaso-nebulizer-for-copd-patients-with-hypoxemia-100595852","NCT07037836","Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia","Tyvaso","Inclusion Criteria\n\n* Outpatients of either gender, age ≥ 40.\n* Clinical evidence of chronic bronchitis (a productive cough lasting more than 3 months within a 2-year period).\n* Current or former cigarette smokers with a smoking history of 20 or more pack-years.\n* Clinical diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by spirometry demonstrating forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \\\u003C 0.70, pre-bronchodilator FEV1 ≥ 30% predicted, and diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 45% predicted.\n* On stable maintenance COPD medications including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), combination inhalers, azithromycin, or roflumilast (with no changes over the past 3 months).\n* Patients with hypoxemia, evidenced by the use of supplemental oxygen at rest or during exercise (≤ 4 liters\u002Fminute).\n* Willing and able to give informed consent and adhere to visit and protocol schedules (consent must be obtained prior to any study procedures).\n* Women of childbearing potential must have a negative serum pregnancy test, confirmed prior to participation in this investigational protocol.\n\nExclusion Criteria\n\n* Upper respiratory tract infection within 6 weeks (participants may be rescreened after this period).\n* History of lung resection surgery or pleural decortication.\n* Previous history of pneumothorax.\n* Imaging evidence of interstitial lung disease, occupational lung disease, or chronic infectious lung disease.\n* History of asthma.\n* History of exposure to occupational or environmental hazards known to cause lung disease.\n* Positive pregnancy test for women of childbearing potential.\n* Major chronic illness that, in the judgment of the study physician, would interfere with participation in the study.\n\nFor Magnetic Resonance Imaging (MRI):\n\n* Contraindications to MRI based on screening questionnaire responses.\n* Participant is pregnant or lactating.\n* Respiratory illness of bacterial or viral etiology within 6 weeks prior to MRI.\n* Known cardiac arrhythmia.\n* Participant does not fit into the hyperpolarized xenon-129 (\\^129Xe) vest coil used for MRI.\n* Participant cannot hold their breath for 10 seconds.\n* Participant is unlikely to comply with instructions during imaging.","40 Years",{"count":638,"type":21},10,[640],"PHASE2","The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \\[DLCO\\] ≥45%).\n\nThe main questions it aims to answer are:\n\n1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)?\n2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \\[RBC\\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)?\n3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil?\n\nParticipants will:\n\n* Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated.\n* Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange.\n* Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study.\n* Be monitored for adverse events, with a phone check-in midway through and after the treatment period.",[477,28],[634,644,28],"COPD","2025-10-29",{"date":647,"type":42},"2025-10-30",{"date":649,"type":42},"2025-09-29",{"date":651,"type":21},"2027-07-01",{"name":653,"class":49},"Bastiaan Driehuys"]